The aim of this study is to investigate i) whether two biomarkers (urine NAG, urinary cystatin C) could be predictive factor in patient with liver cirrhosis, , and ii) whether these biomarkers can predict response of terlipressin.
Acute kidney injury (AKI) in patients with liver cirrhosis is sometimes accompanied by tubular injury which can lead to poor outcome. Current AKI criteria using serum creatinine (Cr) has some limitations to predict reversibility of renal function and discriminate renal parenchymal injury in cirrhotic patients. The aim of this study is to evaluate whether urine biomarkers \[cystatin C, N-acetyl-β-D-Glucosaminidase (NAG)\] can predict survival and response to terlipressin in cirrhotic patients with AKI.
Study Type
OBSERVATIONAL
Enrollment
245
SoonChunHyang University Bucheon Hospital
Bucheon-si, Gyeonggi-do, South Korea
RECRUITINGOverall survival
From date of sample collection until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
Time frame: up to 3 years
Transplantation free survival
From date of sample collection until the date of first liver transplantation or date of death from any cause, whichever came first, assessed up to 3 years
Time frame: up to 3 years
Regression of acute kidney injury
Regression is defined as movement of AKI to a lower stage and decrease of serum creatinine
Time frame: up to 1 month
Recurrence of acute kidney injury
From sample collection day to elevation day of creatinine
Time frame: up to 1 year
Progression to chronic kidney disease
From sample collection day to progression to CKD
Time frame: 1 year
Response rate to terlipressin
If reduction of creatinine 0.3mg/dL from the baseline
Time frame: 1 week
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.